drugset / Trial / NCT00225355
Rosiglitazone Versus Placebo in Chronic Stable Angina
Phase 4
Terminated
80 enrolled
University of Glasgow
British Heart Foundation · collabGlaxoSmithKline · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
We wish to see if the drug rosiglitazone, currently used in the treatment of type 2 diabetes, could be used as a new treatment for angina when compared with placebo in overweight subjects who do not have overt diabetes. The drug will be given for 3 months and the subjects will be have their angina tested, by way of exercise testing, angina quality of life questionnaire and 24-hour ECG monitoring before and after using the drug.
Timeline
- Start
- 2006-02
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosiglitazone | Small molecule | — | — |